Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664754 · ClinicalTrials.gov registry record · Phase 1
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
A Phase 1 study of Stage IV Non-small Cell Lung Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01664754 is a Phase 1 study of Stage IV Non-small Cell Lung Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 8 participants, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01664754, a Phase 1 study of Stage IV Non-small Cell Lung Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of exemestane in combination with pemetrexed disodium and carboplatin in treating post-menopausal women with stage IV non-small cell lung cancer. Exemestane may stop the growth of tumor calls by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving exemestane together with pemetrexed disodium and carboplatin may kill more tumor cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG carboplatin
- OTHER pharmacological study
- DRUG exemestane
- DRUG pemetrexed disodium
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-09-07 |
| Est. Completion | 2019-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664754
The ClinicalTrials.gov registry entry for NCT01664754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01664754 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01664754 about?
NCT01664754 is a clinical study titled "Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer". This phase I trial studies the side effects and best dose of exemestane in combination with pemetrexed disodium and carboplatin in treating post-menopausal women with stage IV non-small cell lung cancer. Exemestane may stop the growth of tumor calls by blocking some of the enzymes need for cell grow...
What is the current status of trial NCT01664754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-09-07. Estimated completion is 2019-01-11.
What conditions does trial NCT01664754 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT01664754?
The interventions under investigation include: laboratory biomarker analysis (OTHER), carboplatin (DRUG), pharmacological study (OTHER), exemestane (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT01664754?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01664754 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 1
-
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.